South Korea-based Coreline Soft has launched an AI platform in Germany designed to meet the country’s national reimbursement requirements for lung cancer screening.
Germany's lung cancer screening program entered full implementation in April 2026, with AI-assisted analysis now a mandatory requirement at every reading stage for reimbursement eligibility under the country's statutory health insurance system. The program is structured around eight dedicated billing codes with extrabudgetary funding, the company said.
Coreline Soft's AVIEW HUB platform manages multisite workflows, second reading, and consensus processes across screening networks, pairing with the AVIEW LCS Plus tool for AI-assisted nodule detection and analysis. The platform includes double-reading workflow management, automatic discordance alerts, GDPR-compliant data handling, and longitudinal follow-up functions for nodule change analysis, according to the firm.
Coreline Soft will demonstrate AVIEW HUB at the German Congress of Radiology (RöKo) 2026 in May.
